Huada Gene achieved a revenue of 3.161 billion yuan in the first half of the year, and the steady layout continued to cultivate the international market

On the evening of August 24th, Huada Gene disclosed in the semi -annual report of 2022. In the first half of the year, the company realized operating income of 3.1061 billion yuan, and its net profit was 606 million yuan.

In the first half of 2022, due to the decline in the global new crown nucleic acid reagent and detection unit price, and the changes in some countries and regions, the business revenue related to the new crown -related business was decreased from the same period in 2021. In terms of the company's conventional business sectors, fertility health and infection businesses have declined compared with the same period of the previous year. The income of tumor prevention and control business and multi -sets of big data and synthetic business has increased compared with the same period of the previous year.

Perseverance with constant products "internal skills", comprehensively expand the advantages of business system

During the reporting period, Huada Gene insisted on research and development investment and technology upgrades, and R & D investment increased by 24.17%year -on -year. In terms of clinical application of product iteration and reserve, the company continues to carry out forward -looking layout, quickly promotes the development of products such as core patented technology and big data of crowds, tumor screening, and infection prevention and control. Actively transform research results and continue to improve the technical and market advantages of various business systems.

In terms of fertility and health business, during the reporting period, the company has newly developed the testing kit of POCT detection kit of non -invasive sickness cell anemia gene detection technology and sickle cell anemia, optimizing and upgrading the amplifier of the amnesia ® monocyte genetic disease. Screening and other products. It is worth noting that the company's α and β thalassemia gene detection kits have been registered through the State Drug Administration. It is the first domestic thalassemia gene detection kit that has been approved based on high -throughput sequencing technology. The lack of and non -missing variations of β thalassemia has effectively filled the gap in the lack of detection of domestic β thalassemia genes.

In terms of tumor prevention and control business, the company's product pipelines have been further enriched, and the accurate prevention and control closed -loop system has been implemented. The influence of the field of tumor prevention and control business is becoming increasingly significant. In the first half of the year, on the basis of the existing pre -, sieve, diagnosis, and monitoring product closed -loop system, Huada Gene launched products such as Hua Changkang ® hidden blood testing, Huayanan® endometrial cancer molecular type testing, etc. And upgraded Huaxuean TM leukemia gene test (DNA+RNA), 100 yuan -level non -invasive liver cancer gene test products Huaganning®, further enriched the tumor prevention and control product pipeline, and promoted the customized detection Regional core hospitals achieve clinical coverage.

In terms of infection prevention and control business, the company continues to optimize the core product PMSEQ® pathogenic microbial high -throughput genetic testing, significantly improved the detection sensitivity, and the detection timeliness is increased to 24 hours. The amount of quantitative growth is growing. In addition, Huada Gene has given full play to the advantages of high -throughput sequencing technology in the detection of major infectious diseases. After the emergence of severe acute hepatitis and monkey acne epidemic in children's unknown causes, Huada gene responded rapidly and developed prostate viruses urgently. Products such as type 41 nucleic acid detection and PMSEQ pathogenic screening plan, monkey acne test kit and other products have effectively helped the global public health prevention and control.

In terms of multiple groups of big data services and synthetic services, the company mainly promotes DNBELABC4 RNA-SEQ single-cell products based on domestic single-cell independent platform service models, and launch a variety of application scenarios, including brain science, map development, disease line queue, etc. A variety of models can combine multiple groups of scientific technologies to meet the needs of different customers, and provide service support for multi -dimensional single -cell level research for universities, research institutes and other scientific research users; Time and space -angle positioning tissue types of cell expression to achieve more refined single -cell research. At the same time, an important breakthrough in the research and development of in vitro genome splicing technology, in vitro synthesis lengths exceeded 500KB.

In terms of comprehensive solutions for precision medical testing, Huada Gene rely on its strong research and development capabilities, rich clinical transformation capabilities and high -performance autonomous platforms, and through the deep cultivation of many years, it has provided a new type of medical synthesis that runs through the entire life cycle for the realization of health China. Solution, in the future, will continue to use the channels of "fire eye" as the starting point, explore the transformation of overseas conventional businesses, and further open up an incremental space to empower the global life and health industry.

The application needs of genomics ushered in the explosion period, and multi -dimensional strategic deployment deep overseas overseas

At present, the genome industry is in a new stage of demand. With the rapid development of multiple groups represented by genomics, huge changes have occurred in the fields of clinical diagnosis, drugs, individualized therapy, and agriculture. The demand for multiple groups of academic applications is also increasing. In the future, the needs of precision medicine and even life science and technology applications with genomics as the core will further expand.

In order to seize the emerging opportunities of genomics applications, as the founder of the Chinese gene industry, Huada Gene adheres to the vision of "genetic technology benefit humanity" and actively contributes to the development of the global public health industry and the development of precision medical industries. The company expands the development of precision medical care to the world, carrying forward professional technology, efficient services, and the cost advantage of domestic independent platforms. Relying on the existing "Fire Eye" laboratory channel advantages, accelerate the scale of conventional business transformation, and grasp the current global precision. The opportunity for the construction of the medical service system to expand the capacity, and comprehensively deepen the international business expansion in product qualifications, localized strategic planning, and quality system. As of the first half of 2022, the company has obtained a variety of heavy products in the EU CE, India, Thailand, Saudi Arabia and other overseas national qualifications, laying the foundation for the long -term local development and cooperation of overseas business. On the other hand, Huada Gene focuses on injecting living forces for overseas business. The company implements the strategy of "front shop and back factory", promotes the construction of IVD factories, and is deeply rooted in important overseas markets. At present, IVD factories have been established in Ethiopia, and Saudi IVD factories are being prepared to ensure the supply of upstream core links and form regional business radiation.

The company continues to explore the hierarchical diagnosis and treatment solutions and localized closed -loop models that meet various national conditions. Now some countries and regions have launched precision medical livelihood projects. Based on the "dual -line layout" of products and services, the integration of public health prevention and control will be integrated The solution is exported overseas, and Chinese technology has expanded globally through engineering empowerment, helping to further expand the international market layout and achieve sustainable development of overseas business.

After the accumulation of accumulation since the epidemic, Huada Gene has created a tested high -level technology team, and formed an advanced and perfect multi -group science and technology platform to empower business. Over the years, Huada Gene has always maintained the leading position of the industry. With the genetic industry ushered in a new wave of development opportunities, the company will continue to lead the technology and application of China's genetic and applications to achieve scientific and technological innovation and industrial breakthroughs.

(This article does not represent the first financial point of view, and it is published for the purpose of passing business information.)

- END -